Claims for Patent: 5,196,320

Summary for Patent: 5,196,320

Title:	Method of producing engineered binding proteins
Abstract:	Disclosed are methods of producing fusion proteins including those with dual biological activities. These methods include the provision of a first and second DNA sequence encoding a first and second polypeptide, repectively, the digestion of the first DNA sequence at a restriction site adjacent its 3\' or 5\' terminus, and the ligation of a linker/adapter sequence (l/a) to the restricted end of the first DNA sequence, thereby forming a cassette. The l/a includes, at one end, that portion of the first DNA sequence extending from its terminus nearest the restriction site to the restriction site, and at the other end, one side of a splice site. A eucaryotic host cell is transfected with the cassette and the second DNA sequence having, at one end, one side of a splice site compatible with the side of the splice site on the l/a. The transfected host cell is cultured to express the transfected DNA as a single chain fusion protein.
Inventor(s):	Gillies; Stephen D. (Hingham, MA)
Assignee:	Abbott Biotech, Inc. (Needham Heights, MA)
Application Number:	07/810,522
Patent Claims:	1. A method of producing an engineered binding protein comprising the steps of: (a) providing a cDNA encoding an immunoglobulin variable (V) region and defining a restriction site located 5' to and adjacent the 3' end of said V region; (b) digesting said V region-encoding cDNA at said restriction site to produce a new 3' end; (c) ligating a linker/adapter (1/a) DNA to said new 3' end to produce a V region cassette, said 1/a DNA comprising, in sequence from tis 5' end: a DNA encoding the removed portion of said V regionencoding cDNA; and a splice donor site; (d) transfecting a eucaryotic host cell with a vector comprising said cassette nd a second DNA comprising: DNA defining a splice acceptor site at its 5' end, compatible with said splice donor site on said 1/a DNA and DNA encoding a human constant region domain; and (e) culturing said transfected host cell to co-express said cassette and said second DNA as a single chain, fused binding protein. 2. The method of claim 1 wherein said cDNA provided in step (a) comprises cDNA encoding an immunoglobulin light chain V region. 3. The method of claim 2 wherein said cDNA encodes a non-human immunoglobulin V region. 4. The method of claim 3 wherein said cDNA encoding an immunoglobulin V region encodes a murine V region. 5. The method of claim 1 wherein said cDNA provided in step (a) comprises cDNA encoding an immunoglobulin heavy chain V region. 6. The method of claim 1 wherein said 1/a DNA ligated in step (c) comprising greater than about 80 nucleotide bases. 7. The method of claim 1 wherein said 1/a DNA ligated in step (c) comprising a universal intron including greater than about 80 nucleotide bases.

Details for Patent 5,196,320

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2010-03-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2010-03-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2010-03-23